Skip to main content
. Author manuscript; available in PMC: 2023 Sep 1.
Published in final edited form as: Cancer Discov. 2023 Mar 1;13(3):580–597. doi: 10.1158/2159-8290.CD-22-0964

Fig. 4. CART19/20 cell therapy is highly effective in treating relapsed/refractory non-Hodgkin lymphomas.

Fig. 4.

(A) Representative PET scans of patients treated with CART19/20. (B) Overall survival and progression-free survival curves from the time of CART19/20 cell infusion. (C) PET scan obtained at screening for Patient 003, indicating pulmonary involvement of PMBCL. (D) Immunohistochemistry (IHC) analysis of Patient 003 tissue biopsies; original magnification x160. Supraclavicular lymph node biopsy obtained at screening and bone-marrow biopsy obtained 14 days post CART19/20 infusion were analyzed by IHC. Results reveal rapid emergence of a CD19−CD20−BCL6−cMYC− tumor population within 14 days of CART19/20 treatment.